| Budget Amount *help |
¥45,000,000 (Direct Cost: ¥45,000,000)
Fiscal Year 2009: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2008: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2007: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2006: ¥9,000,000 (Direct Cost: ¥9,000,000)
Fiscal Year 2005: ¥9,000,000 (Direct Cost: ¥9,000,000)
|
|---|
| Research Abstract |
For the purpose of development of the immunotherapy targeting cell surface antigenic molecules, we evaluated dendritic cell therapy using mRNA as antigen and antibody therapy in this study. For dendritic cell therapy, we performed the preclinical studies with several mouse models and then its clinical application in liver, biliary and pancreatic cancer patients. With regard to antibody therapy, we examined the molecules that express in cancer stem cells and found that a receptor molecule, Frizzled-7, is highly expressed in colorectal cancer and could be a potential therapeutic target.
|
